

Datasheet: HCA360

Description:	HUMAN ANTI DURVALUMAB
Specificity:	DURVALUMAB
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD41313ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Drug
Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Durvalumab
Specificity	Human Anti-Durvalumab Antibody, clone AbD41313ia is a paratope specific, inhibitory anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal

antibody drug durvalumab. The antibody does not recognize free PD-L1 nor durvalumab in complex with PD-L1.

Clone AbD41313ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 14 nM, and is one of two antibodies with different affinities offered for ADA assays.

[ADA bridging ELISA](#)

HCA360 may also be used as the detection antibody together with the Anti-Durvalumab monovalent Fab antibody [TZA004](#), as capture antibody in a pharmacokinetic (PK) assay to measure free durvalumab captured via immobilized PD-L1.

[PK bridging ELISA](#)

Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells.

[View a summary of all anti-durvalumab antibodies](#)

Affinity	The intrinsic affinity of the monovalent form of Human anti Durvalumab antibody, clone AbD41313ia is $K_D = 14$ nM as measured by real time, label free molecular interaction analysis on immobilized Durvalumab.
ELISA	This product may be used in a direct or indirect ELISA or as a detection reagent for durvalumab in a PK bridging ELISA together with TZA004 (AbD41327) as the capture reagent. It can also be used to develop and calibrate anti drug antibody (ADA) assays to measure the ADA response in patient sera together with HCA359 Protocol: ADA bridging ELISA .
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch

Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Imfinzi is a trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse technology.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual .

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI DURVALUMAB \(HCA359\)](#)

ELISA Matched Pair - Capture Antibody

[HUMAN ANTI DURVALUMAB \(TZA004\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M414178:221205'

Printed on 05 Dec 2022